LXRX (STOCKS)
Lexicon Pharmaceuticals, Inc.
$1.740000
+0.020000 (+1.16%)
Prev close: $1.720000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Michael Exton
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $726.61M
- Employees
- 103
- P/E (TTM)
- -12.32
- P/B (TTM)
- 5.81
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
3
Strong Buy
5
Buy
3
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$-0.04 | $-0.07 | +0.0304 | +43.18% |
|
Sep 2025 (Q3)
|
$-0.04 | $-0.07 | +0.0273 | +40.56% |
|
Jun 2025 (Q2)
|
$0.01 | $-0.08 | +0.0891 | +112.64% |
|
Mar 2025 (Q1)
|
$-0.07 | $-0.10 | +0.0295 | +29.65% |
Financial Statements
| Revenues | $49.80M |
| Benefits Costs and Expenses | $98.71M |
| Cost Of Revenue | $274.00K |
| Costs And Expenses | $98.71M |
| Gross Profit | $49.53M |
| Operating Expenses | $98.44M |
| Selling, General, and Administrative Expenses | $37.32M |
| Research and Development | $61.12M |
| Operating Income/Loss | -$48.91M |
| Income/Loss From Continuing Operations After Tax | -$50.34M |
| Income/Loss From Continuing Operations Before Tax | -$48.91M |
| Net Income/Loss | -$50.34M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$50.34M |
| Net Income/Loss Available To Common Stockholders, Basic | -$50.34M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$0.14 |
| Diluted Earnings Per Share | -$0.14 |
| Basic Average Shares | 363,053,000 |
| Diluted Average Shares | 363,053,000 |
| Assets | $184.99M |
| Current Assets | $101.90M |
| Inventory | $281.00K |
| Other Current Assets | $101.61M |
| Noncurrent Assets | $83.09M |
| Fixed Assets | $1.86M |
| Other Non-current Assets | $81.23M |
| Liabilities | $77.45M |
| Current Liabilities | $20.87M |
| Accounts Payable | $3.08M |
| Wages | $6.42M |
| Other Current Liabilities | $11.37M |
| Noncurrent Liabilities | $56.58M |
| Equity | $107.54M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $107.54M |
| Liabilities And Equity | $184.99M |
| Net Cash Flow From Operating Activities | -$67.85M |
| Net Cash Flow From Operating Activities, Continuing | -$67.85M |
| Net Cash Flow From Investing Activities | $113.02M |
| Net Cash Flow From Investing Activities, Continuing | $113.02M |
| Net Cash Flow From Financing Activities | -$48.50M |
| Net Cash Flow From Financing Activities, Continuing | -$48.50M |
| Net Cash Flow | -$3.33M |
| Net Cash Flow, Continuing | -$3.33M |
| Comprehensive Income/Loss | -$50.43M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$50.43M |
| Other Comprehensive Income/Loss | -$50.43M |